Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004032 · ClinicalTrials.gov registry record · Phase 1
Tumor Vaccine and Interferon Gamma in Treating Patients With Refractory Epithelial Ovarian Cancer
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT00004032: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00004032 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004032, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
Phase I trial to study the effectiveness of a tumor cell vaccine and interferon gamma in patients with refractory epithelial ovarian cancer. Vaccines made from a person's cancer cells may make the body build an immune response to and kill their tumor cells. Combining vaccine therapy with interferon gamma may be a more effective treatment for epithelial ovarian cancer
Interventions
- OTHER laboratory biomarker analysis
- BIOLOGICAL ALVAC-hB7.1
- BIOLOGICAL recombinant interferon gamma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 1997-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004032
The ClinicalTrials.gov registry entry for NCT00004032 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT00004032 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004032 about?
NCT00004032 is a clinical study titled "Tumor Vaccine and Interferon Gamma in Treating Patients With Refractory Epithelial Ovarian Cancer". Phase I trial to study the effectiveness of a tumor cell vaccine and interferon gamma in patients with refractory epithelial ovarian cancer. Vaccines made from a person's cancer cells may make the body build an immune response to and kill their tumor cells. Combining vaccine therapy with interferon ...
What is the current status of trial NCT00004032?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 1997-10.
What interventions are being tested in trial NCT00004032?
The interventions under investigation include: laboratory biomarker analysis (OTHER), ALVAC-hB7.1 (BIOLOGICAL), recombinant interferon gamma (BIOLOGICAL).
Who is sponsoring clinical trial NCT00004032?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.